AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent Multiple Myeloma

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFYยฎ+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107Phase 362 sites๐Ÿ“ Bullhead City๐Ÿ“ Huntington Park๐Ÿ“ St. Petersburg Grifols Therapeutics LLC ยท Tests: Xembify, Placebo A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites๐Ÿ“ Bullhead City๐Ÿ“ Los Angeles๐Ÿ“ Pembroke Pines GlaxoSmithKline ยท Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044Phase 116 sites๐Ÿ“ Phoenix๐Ÿ“ Orange๐Ÿ“ Jacksonville Jiangsu Simcere Pharmaceutical Co., Ltd. ยท Tests: SIM0500 A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. NCT06232096Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Mabworks Biotech Co., Ltd. ยท Tests: MBS314 Injection A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites๐Ÿ“ Denver๐Ÿ“ Denver๐Ÿ“ Columbia SCRI Development Innovations, LLC ยท Tests: Elranatamab, Tocilizumab Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure Plan Development for Giving Teclistamab in the Outpatient Setting NCT06251076Phase 41 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Teclistamab, Tocilizumab A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma NCT07105059Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Teclistamab, Mezigdomide A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma NCT06732232EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD20/BCMA CAR-T A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma NCT07609030NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616Phase 1, Phase 210 sites๐Ÿ“ Birmingham๐Ÿ“ San Francisco๐Ÿ“ Atlanta ModernaTX, Inc. ยท Tests: mRNA-2808 Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse NCT06827860Phase 21 site๐Ÿ“ New York Larysa Sanchez ยท Tests: Talquetamab, Daratumumab Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+ NCT06874530n/a1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568Phase 112 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Foshan Excyte Biopharma Ltd ยท Tests: YKST02 A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site๐Ÿ“ Tianjing Shandong New Time Pharmaceutical Co., LTD ยท Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma NCT05565807Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Guangzhou Zhejiang ACEA Pharmaceutical Co. Ltd. ยท Tests: STI-6129 Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse NCT06948084Phase 231 sites๐Ÿ“ Coeur d'Alene๐Ÿ“ Post Falls๐Ÿ“ Sandpoint National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluroโ€ฆ A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site๐Ÿ“ Shanghai Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tabโ€ฆ Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551Phase 1, Phase 23 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ Boston Omar Nadeem, MD ยท Tests: Elotuzumab, Iberdomide, Dexamethasone Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site๐Ÿ“ Camden Roger Strair ยท Tests: Soursop tea Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM NCT05594797Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Wenzhou Hrain Biotechnology Co., Ltd. ยท Tests: Human BCMA Targeted T Cells Injection Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma NCT06465316Phase 117 sites๐Ÿ“ Phoenix๐Ÿ“ Derby๐Ÿ“ Guilford National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide CAR-T in Relapsed/Refractory Multiple Myeloma NCT07689058Phase 22 sites๐Ÿ“ Rawalpindi๐Ÿ“ Rawalpindi Dr. Zaineb Akram ยท Tests: CAR-T Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site๐Ÿ“ Columbus Naresh Bumma ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma NCT07181941Phase 1, Phase 21 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects NCT07280013Phase 119 sites๐Ÿ“ Gilbert๐Ÿ“ Sacramento๐Ÿ“ Santa Monica C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Elranatamab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy